NCT05636774

Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial

Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial - EMPATICC (INCOR1)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 97 (actual)
• Sponsor: University Hospital, Essen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (incl. fibrosis and apoptosis) in end-stage cancer patients, causing heart failure like syndrome with development of congestion, dyspnoea and severely reduced physical functioning. The present trial aims to evaluate, if a heart failure medication improves the self-care ability and self-reported health care status of patients with with advanced cancer receiving specialized palliative care.

Conditions

• Patients With Advanced Cancer Receiving Specialized Palliative Care

Interventions

Type	Name	Description
DRUG	Heart failure medication	Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
DRUG	Placebo	Placebo tables / infusion

Timeline

• Start date: 2022-12-12
• Primary completion: 2025-01-31
• Completion: 2025-03-01
• First posted: 2022-12-05
• Last updated: 2025-08-22

Locations

1 site across 1 country: Germany